EXEL - Exelixis, Inc.
| Previous Close | 23.22 |
| Open | 23.20 |
| Bid | 22.00 x 1800 |
| Ask | 26.59 x 4000 |
| Day's Range | 22.77 - 23.32 |
| 52 Week Range | 13.42 - 25.31 |
| Volume | 2,279,570 |
| Avg. Volume | 3,903,608 |
| Market Cap | 6.963B |
| Beta (3Y Monthly) | 2.03 |
| PE Ratio (TTM) | 10.50 |
| EPS (TTM) | 2.21 |
| Earnings Date | Apr 30, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.00 |
- Benzinga•8 days ago
Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'
Morgan Stanley has dropped its bearish stance on Exelixis, Inc. (NASDAQ: EXEL ), although the research firm hasn't gained enough confidence to recommend buying the drugmaker's stock. The Analyst Analyst ...
- Schaeffer's Investment Research•8 days ago
Signal Says Buy Options Insurance on This Biotech
The shares are just off a new high, but could cool off soon, if history repeats
- Zacks•11 days ago
Exelixis (EXEL) Gains As Market Dips: What You Should Know
Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.
- American City Business Journals•12 days ago
How a biotech company navigated bay bureaucracy to set up a commuter ferry service
The company took a crash course in trying to set up a transbay ferry service to get employees from South San Francisco to its new headquarters in Alameda.
- Zacks•12 days ago
Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com•13 days ago
5 Biotech Stocks to Keep an Eye on in 2019
The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).
- Simply Wall St.•13 days ago
Why Exelixis, Inc. (NASDAQ:EXEL) Is An Attractive Investment To Consider
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Exelixis, Inc. (NASDAQ:EXEL) due to its excellent fundamentals in more thanRead More...
- Zacks•14 days ago
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
- Zacks•17 days ago
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.
- Business Wire•21 days ago
Exelixis Announces Webcasts of Investor Conference Presentations in March
̶ Presentations to be webcast on www.exelixis.com ̶
- Motley Fool•21 days ago
3 Best Biotech Bargain Stocks on the Market Right Now
If you're looking to buy biotech stocks on the cheap, these three could be right up your alley.
- GuruFocus.com•last month
Exelixis Inc (EXEL) Files 10-K for the Fiscal Year Ended on December 31, 2018
Exelixis Inc is a biotechnology company. Warning! GuruFocus has detected 2 Warning Sign with DVA. For the last quarter Exelixis Inc reported a revenue of $228.6 million, compared with the revenue of $120.1 million during the same period a year ago.
- Motley Fool•last month
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
- Zacks•last month
New Strong Sell Stocks for February 15th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•last month
Implied Volatility Surging for Exelixis (EXEL) Stock Options
Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.
- CNBC•last month
Cramer's lightning round: These are the two pot stocks I'm recommending
Jim Cramer rattles off his responses to callers' stock questions, including one on a top cannabis play.
- Motley Fool•last month
Exelixis Grabs 90% of First Place
In a multibillion dollar cancer-treatment market, a solid second isn't too shabby.
- Zacks•last month
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
- TheStreet.com•last month
Exelixis Rises as Fourth-Quarter Earnings Beat Estimates
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
- TheStreet.com•last month
These 'Small Ball' Names Will Outperform the Market in 2019
This is the last heavy week of fourth quarter reports from companies within the S&P 500, with some 60 names reporting during the week. Earnings growth has been better than expected to this point with year-over-year profit growth north of 16%. While not the 20%-plus we have seen over the past few quarters, it is solidly above the approximate 14% rise that was the consensus before fourth quarter results started to hit the wires.
- Benzinga•last month
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT
Q4 2018 Exelixis Inc Earnings Call
Motley Fool•last monthExelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript
EXEL earnings call for the period ending December 31, 2018.
- Associated Press•last month
Exelixis: 4Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had profit of $1.15. Earnings, adjusted for pretax gains, came to 37 cents per share. The results beat Wall Street expectations. The ...
- Zacks•last month
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
